Interferon-beta
-
Subject Areas on Research
- A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection.
- A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study.
- Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
- An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage.
- Bone protection by inhibition of microRNA-182.
- Cloned endothelium derived from autoimmune vascular disease retain structural and functional characteristics of normal endothelial cells.
- Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals.
- Cytokine expression by models of human trophoblast as assessed by a semiquantitative reverse transcription-polymerase chain reaction technique.
- Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta.
- Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts.
- Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling.
- Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
- GW112, a novel antiapoptotic protein that promotes tumor growth.
- Gonococcal lipooligosaccharide suppresses HIV infection in human primary macrophages through induction of innate immunity.
- IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors.
- Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling.
- Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
- In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
- Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.
- Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta.
- Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma.
- Interferon in the treatment of cutaneous T-cell lymphoma.
- Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele.
- Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome.
- Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment.
- NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses.
- Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter.
- Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate.
- Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages.
- Regulation of microglial function by interferons.
- STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection.
- The IFN-inducible GTPase LRG47 (Irgm1) negatively regulates TLR4-triggered proinflammatory cytokine production and prevents endotoxemia.
- The induction of HMGB1 release from RAW 264.7 cells by transfected DNA.
- The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes.
- Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
- Type I interferon pathway in adult and juvenile dermatomyositis.
- Update: biomarkers for idiopathic inflammatory myopathies.
- Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus.
- [NLRP3 inflammasome and multiple sclerosis/EAE].
-
Keywords of People
- Shinohara, Mari L., Associate Professor of Immunology, Immunology